


**Supplementary Figure 1. Hepatic NR, NAR, and Me2PY concentrations after gavage of NR, Nam and NA**



Either saline or equivalent moles of NR, NA or Nam were administered to male C57BL6/J mice by gavage. To control for circadian effects, gavage was performed at indicated times prior to a common ~2 pm sacrifice. In the left panels, the hepatic concentrations of each metabolite (pmol per mg of wet tissue weight) are shown as a function of the four gavages. In the right panels, the baseline subtracted 12-hour areas under the curve are shown. Left panels: ‡ p-value < 0.05; †† p-value < 0.01; ††† p-value < 0.001 Nam vs NA; † p-value < 0.05; †† p-value < 0.01; ††† p-value < 0.001 Nam vs NR; # p-value < 0.05; ### p-value < 0.01; #### p-value < 0.05 NA vs NR; Right panel: \* p-value < 0.05; \*\* p-value < 0.01; \*\*\* p-value < 0.001.

**Supplementary Table 1. PBMC NAD<sup>+</sup> metabolites (μM) in a 52 year-old male who orally ingested 1000 mg NR CI for 7 consecutive days**

Time (hr)	NAD <sup>+</sup>	NADP <sup>+</sup>	NaAD	NMN	ADPR	Nam	MeNam	Me4PY	Me2PY
0	12	9.1	<0.02	0.68	0.70	3.2	0.06	0.20	1.1
0.3	27	23	<0.02	1.8	3.3	4.5	0.14	0.44	2.2
0.6	17	13	<0.02	1.4	2.1	7.1	0.08	0.57	3.1
1	24	13	<0.02	1.3	1.3	3.2	0.20	0.59	3.4
1.4	19	11	<0.02	1.1	1.3	3.7	0.15	0.64	3.1
2.7	12	6.9	<0.02	0.77	0.85	2.9	0.13	0.53	2.8
4.1	42	27	<0.02	2.7	3.4	4.9	0.32	1.9	11
7.7	43	27	0.51	2.6	2.5	5.9	0.49	3.5	17
8.1	50	33	0.91	2.9	3.5	5.7	0.60	4.4	22
23.8	32	17	0.37	1.9	2.5	2.6	0.25	1.9	8.8
167.6	38	12	0.45	1.1	2.1	3.2	0.66	2.5	11

**Supplementary Table 2. Plasma NAD<sup>+</sup> metabolites (μM) in a 52 year-old male who orally ingested 1000 mg NR CI for 7 consecutive days**

Time (hr)	Nam	MeNam	Me4PY	Me2PY
0	0.70	0.10	0.60	2.2
0.6	0.90	0.40	1.1	5.7
1	1.2	0.60	1.4	5.7
1.4	1.1	0.50	1.4	6.6
2.7	0.90	0.60	1.8	7.5
4.1	1.2	0.80	2.6	10
7.7	1.1	0.70	3.2	13
8.1	0.60	0.90	3.8	14
23.8	0.80	0.90	3.9	14
167.6	1.5	2.1	4.6	17

**Supplementary Table 3. Urinary NAD<sup>+</sup> metabolites (μmol/mmol creatinine) in a 52 year-old male who orally ingested 1000 mg NR CI for 7 consecutive days**

Time (hr)	Nam	MeNam	Me4PY	Me2PY
Pre-1 <sup>st</sup> dose	0.26	5.5	2.8	13
0 - 4.1	0.16	6.5	3.8	20
4.1 - 7.7	2.9	26	21	180
8.1 - 12	1.8	26	24	99
Pre-2 <sup>nd</sup> dose	1.4	29	29	108
Pre-5 <sup>th</sup> dose	1.2	30	24	80

**Supplementary Table 4. NAD<sup>+</sup> Metabolite AUC Increases as a Function of Single Doses of NR**

Metabolite	NR Dose (mg)	AUC Increase from Baseline (%)			Comparison (Tukey Test)	
		Mean	SEM	N	vs. 100 mg	vs. 300 mg
NMN	100	13	14	8		
	300	47	38	10	ns	
	1000	23	15	8	ns	ns
NAD <sup>+</sup>	100	48	15	12		
	300	59	40	12	ns	
	1000	92	49	12	ns	ns
Nam	100	14	7	12		
	300	19	21	12	ns	
	1000	16	10	12	ns	ns
MeNam	100	12	20	9		
	300	63	22	11	ns	
	1000	231	42	9	***	**
me2PY	100	53	14	10		
	300	201	88	9	ns	
	1000	609	146	9	**	*
NAAD	100	705	323	10		
	300	1287	480	10	ns	
	1000	2873	1250	10	*	ns

\* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001